Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIST study
2023-505940-20-00Phase 4Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Sep 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of romosozumab and zoledronic acid in osteoporosis (3 arms), sponsored by Aarhus University Hospital. Primary endpoint: Change in total hip bone mineral density. Planned start Sep 2023; status: authorised.
02
Drugs
romosozumabzoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2023-505940-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505940-20-00.